No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group

References

• Druker BJ, Sawyers C, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of CML and ALL with the Philadelphia chromosome. New Engl J Med. 2001;344:1038–1042.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691–709.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–1035.
   PubMed Web of Science ®Google Scholar
• Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35(3):298–305.
   PubMed Web of Science ®Google Scholar
• Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846–854.
   PubMed Web of Science ®Google Scholar
• Campiotti L, Suter MB, Guasti L, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer. 2017;77:48–56.
   PubMed Web of Science ®Google Scholar
• Clark RE, Polydoros F, Apperley JF, et al. Initial reduction of therapy prior to complete treatment discontinuation in chronic myeloid leukemia: final results of the British DESTINY study. Lancet Haematol. 2019;6(7):e375–e383.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENEST freedom study. Leukemia. 2017;31(7):1525–1531.
   PubMed Web of Science ®Google Scholar
• Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–757.
   PubMed Web of Science ®Google Scholar
• Iman M, Khansefid Z, Davood A. Modeling and proposed molecular mechanism of hydroxyurea through docking and molecular dynamic simulation to curtail the action of ribonucleotide reductase. Recent Pat Anticancer Drug Discov. 2016;11(4):461–468.
   PubMed Web of Science ®Google Scholar
• Krahl R, Waller M, Metzke S, et al. Cytogenetic monitoring of CML patients treated initially with cyclic Hydroxyurea (CHD-HU) followed by interferon-alpha (IFN) or low-dose cytosine arabinoside (LD-ARA-C) or CHD-HU maintenance. Onkologie. 1995;18:116.
   Google Scholar
• Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993;82(2):398–407.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Berger U, Pfirrmann M, et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia. 2003;17(8):1529–1537.
   PubMed Web of Science ®Google Scholar
• Petzer AL, Hochenburger E, Haun M, et al. High-dose hydroxyurea plus G-CSF mobilize BCR-ABL-negative progenitor cells (CFC, LTC-IC) into the blood of newly diagnosed CML patients at any time of hematopoietic regeneration. J Hematother Stem Cell Res. 2002;11(2):293–300.
   PubMedGoogle Scholar
• Deininger M, Pönisch W, Krahl R, et al. Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens. Bone Marrow Transplant. 2001;27(11):1125–1132.
   PubMed Web of Science ®Google Scholar
• Thiesing JT, Ohno-Jones S, Kolibaba KS, et al. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96(9):3195–3199.
   PubMed Web of Science ®Google Scholar
• Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97(7):1999–2007.
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337(4):223–229.
   PubMed Web of Science ®Google Scholar
• Deininger M, Krahl R, Pönisch W, et al. Treatment of chronic phase CML: equal efficacy but less toxicity of interferon-alpha plus hydroxyurea (IFN/HU) compared to IFN plus cytarabin (IFN/ARA-C). Preliminary results from a randomized trial by the OSHO. Onkologie. 2000;23:137.
   Google Scholar
• Pfirrmann M, Hochhaus A, Lauseker M, et al. Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia. Leukemia. 2011;25(9):1433–1438.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31(11):2398–2406.
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrics. 1983;70(1):41–55.
   Google Scholar
• Rubin DB. Multiple imputation for non-response in Surveys. New York: John Wiley & Sons; 1987.
   Google Scholar
• Clopper C, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404–413.
   Google Scholar
• Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Statist Med. 2007;26(11):2389–2430.
   PubMed Web of Science ®Google Scholar
• Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist. 1988;16(3):1141–1154.
   Web of Science ®Google Scholar
• Bergstralh EJ, Kosanke JL, Jacobsen SJ. Software for optimal matching in observational studies. Epidemiology. 1996;7(3):331–332.
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90(11):850–858.
   PubMedGoogle Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686–692.
   PubMed Web of Science ®Google Scholar
• Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48–56.
   PubMed Web of Science ®Google Scholar
• Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 2001;15(3):342–347.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):1353–1360.
   PubMed Web of Science ®Google Scholar
• Lin C-K, Nguyen TT, Morgan TL, et al. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM. Exp Cell Res. 1998;244(1):1–13.
   PubMed Web of Science ®Google Scholar
• Johnson KR, Young KK, Fan W. Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy. Clin Cancer Res. 1999;5(9):2559–2565.
   PubMed Web of Science ®Google Scholar
• Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol. 2013;169(8):1693–1707.
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99(1):319–325.
   PubMed Web of Science ®Google Scholar
• Herr R, Ferguson J, Myers N, et al. Cigarette smoking, blast crisis, and survival in chronic myeloid leukemia. Am J Hematol. 1990;34(1):1–4.
   PubMed Web of Science ®Google Scholar
• Mazza E, Brandes A, Zanon S, et al. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2016;77(1):115–120.
   PubMed Web of Science ®Google Scholar